MMP9 and non-small cell lung carcinoma: To validate the prognostic power of the IHC panel comprising PAI-2 and MMP-9 discovered in our derivation cohort, we further conducted the survival analysis and ROC curve analysis in a validation cohort with 91 NSCLC patients.